Clearmind Medicine Inc. Secures Patent Approval in Hong Kong for Binge Behavior Regulator

LOS ANGELES- Clearmind Medicine Inc., a clinical biotech company specializing in psychedelic-derived therapeutics, has announced a significant advancement in its MEAI-based binge behavior regulator program. The company received patent approval from the Hong Kong Patent Office for its innovative use of primary amine aminoindan compounds to regulate binge behavior.

The patent covers the use of these compounds, including the company’s flagship molecule, 5-methoxy-2-aminoindan (MEAI). This latest addition extends Clearmind’s intellectual property portfolio, which now includes 28 granted patents across 18 patent families in key jurisdictions such as the US, Europe, China, India, and Hong Kong.

MEAI is designed to reduce the desire to consume alcohol while providing a mild euphoric experience. Clearmind’s primary focus is on treating Alcohol Use Disorder (AUD) and weight loss. The treatment addresses AUD, a condition characterized by an inability to limit alcohol intake despite adverse consequences, ranging from mild to severe. Additionally, MEAI shows potential in treating binge drinking, a significant and potentially fatal health issue.

This patent approval marks a step forward in Clearmind’s mission to develop effective treatments for under-treated health problems through psychedelic-derived therapeutics.